BR112023017702A2 - Degradadores bifuncionais de imunoglobulinas deficientes em galactose - Google Patents

Degradadores bifuncionais de imunoglobulinas deficientes em galactose

Info

Publication number
BR112023017702A2
BR112023017702A2 BR112023017702A BR112023017702A BR112023017702A2 BR 112023017702 A2 BR112023017702 A2 BR 112023017702A2 BR 112023017702 A BR112023017702 A BR 112023017702A BR 112023017702 A BR112023017702 A BR 112023017702A BR 112023017702 A2 BR112023017702 A2 BR 112023017702A2
Authority
BR
Brazil
Prior art keywords
deficient
degraders
biffunctional
galactosis
immunoglobulin
Prior art date
Application number
BR112023017702A
Other languages
English (en)
Portuguese (pt)
Inventor
David Spiegel
M Dubowchik Gene
M Caldwell Reese
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of BR112023017702A2 publication Critical patent/BR112023017702A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112023017702A 2021-03-10 2022-03-10 Degradadores bifuncionais de imunoglobulinas deficientes em galactose BR112023017702A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
BR112023017702A2 true BR112023017702A2 (pt) 2023-12-12

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017702A BR112023017702A2 (pt) 2021-03-10 2022-03-10 Degradadores bifuncionais de imunoglobulinas deficientes em galactose

Country Status (11)

Country Link
US (1) US20240309114A1 (https=)
EP (1) EP4304579A1 (https=)
JP (1) JP2024509282A (https=)
KR (1) KR20230154900A (https=)
CN (1) CN116997337A (https=)
AU (1) AU2022232620A1 (https=)
BR (1) BR112023017702A2 (https=)
CA (1) CA3211335A1 (https=)
IL (1) IL305665A (https=)
MX (1) MX2023010424A (https=)
WO (1) WO2022192478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013274A (es) * 2021-05-17 2023-11-30 Biohaven Therapeutics Ltd Composiciones que incluyen potenciadores de tratamientos conjugados.
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2024228935A1 (en) * 2023-04-29 2024-11-07 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
PL2991683T3 (pl) * 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
SG11201606761RA (en) * 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
PL3145934T3 (pl) * 2014-05-19 2021-08-16 Pfizer Inc. Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

Also Published As

Publication number Publication date
US20240309114A1 (en) 2024-09-19
MX2023010424A (es) 2023-09-18
WO2022192478A1 (en) 2022-09-15
EP4304579A1 (en) 2024-01-17
KR20230154900A (ko) 2023-11-09
CA3211335A1 (en) 2022-09-15
IL305665A (en) 2023-11-01
JP2024509282A (ja) 2024-02-29
AU2022232620A1 (en) 2023-09-21
CN116997337A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
BR112023017702A2 (pt) Degradadores bifuncionais de imunoglobulinas deficientes em galactose
BR112022026401A2 (pt) Conjugados anticorpo-fármaco compreendendo anticorpos anti-b7-h3
BR112023013263A2 (pt) Conjugados anticorpo-fármaco alvejados a b7h4 e métodos de uso dos mesmos
Gorovits et al. Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake
Telleman et al. The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile
NO20071717L (no) Anti-Fc-gamma-RIIB-reseptorantistoff og anvendelser av dette
NO20072670L (no) PLAD domene peptider med okt halveringstid i serum pa grunn av konjugering til domene antistoffer
BRPI0317376B8 (pt) proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
WO2019215510A3 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
WO2021248048A3 (en) Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
AR067995A1 (es) Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminales
MA40913A (fr) Conjugués anticorps-médicament
Getman et al. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions
NO20072751L (no) Bispesifikt domene antistoffer malrettet mot serum albumin og GLP-1 eller PYY
WO2006002438A3 (en) Human monoclonal antibodies to fc gamma receptor i (cd64)
NO924088L (no) Antistoffer, fremgangsmaate for deres fremstilling og anvendelse dera v
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
WO2006102395A3 (en) Delivery systems and methods for diagnosing and treating cardiovascular diseases
MX2024006743A (es) Unidad de union a antigeno ccr8 y usos de los mismos.
MY199140A (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022008653A2 (pt) Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco
BR112022009482A2 (pt) Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo
MX2025004353A (es) Construcciones de proteinas de union a lrrc15 y usos de estas